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Leukocyte trafficking is a key event during autoimmune and inflammatory responses.
The subarachnoid space (SAS) and cerebrospinal fluid are major routes for the migration
of encephalitogenic T cells into the central nervous system (CNS) during experimental
autoimmune encephalomyelitis (EAE), the animal model of multiple sclerosis, and are
sites of T cell activation before the invasion of CNS parenchyma. In particular, autoreactive
Th1 and Th17 cell trafficking and reactivation in the CNS are required for the pathogenesis
of EAE. However, the molecular mechanisms controlling T cell dynamics during EAE
are unclear. We used two-photon laser microscopy to show that autoreactive Th1 and
Th17 cells display distinct motility behavior within the SAS in the spinal cords of mice
immunized with the myelin oligodendrocyte glycoprotein peptide MOG35−55. Th1 cells
showed a strong directional bias at the disease peak, moving in a straight line and
covering long distances, whereas Th17 cells exhibited more constrained motility. The
dynamics of both Th1 and Th17 cells were strongly affected by blocking the integrin
LFA-1, which interfered with the deformability and biomechanics of Th1 but not Th17
cells. The intrathecal injection of a blocking anti-LFA-1 antibody at the onset of disease
significantly inhibited EAE progression and also strongly reduced neuro-inflammation in
the immunized mice. Our results show that LFA-1 plays a pivotal role in T cell motility
during EAE and suggest that interfering with the molecular mechanisms controlling T cell
motility can help to reduce the pathogenic potential of autoreactive lymphocytes.
Keywords: lymphocyte function-associated antigen 1, Th1 and Th17 cells, intra-tissue motility, two-photon laser
microscopy, experimental autoimmune encephalomyelitis
INTRODUCTION
Multiple sclerosis (MS), and its animal model experimental autoimmune encephalomyelitis
(EAE), is now generally accepted as an inflammatory dysfunction with evidence supporting an
autoimmune basis. In particular, leukocyte trafficking from the peripheral circulation to the central
nervous system (CNS) induces tissue damage and activates resident glial cells, disrupting myelin
sheaths and destroying the underlying axons (1). The analysis of T cells infiltrating the CNS during
EAE revealed the presence of both Th1 and Th17 cells, which are potent mediators of inflammation
and autoimmunity (2, 3). In MS patients, both Th1 and Th17 cells seem to be involved in disease
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onset and progression, but their relative contribution to the
pathologies of EAE and MS are not yet well defined (1, 4).
Th1 and Th17 cells may play different roles during
autoinflammatory diseases. In particular, the relative proportion
of Th1 and Th17 cells migrating into the CNS varies among
different mouse strains during EAE. Autoreactive Th1 cells
were prevalent in the inflamed CNS at the disease peak when
EAE was induced by immunizing C57BL/6 mice with myelin
oligodendrocyte glycoprotein (MOG), whereas Th17 cells were
prevalent at the same stage in Swiss Jim Lambert (SJL) mice
immunized with proteolipid peptide (2, 3). Furthermore, the
immunization of mice with distinct MOG epitopes elicited T
cell responses with different Th1:Th17 ratios, depending on
the avidity of T cells for their cognate antigen (5). These data
suggest that the relative contribution of Th1 and Th17 cell
responses during CNS inflammation might vary depending on
the strain of mice and the immunization strategy. Another
important feature is the distinct pathologies induced by Th1 and
Th17 cells. Th1-mediated CNS inflammation is characterized by
infiltratingmacrophages, whereas neutrophils aremore prevalent
when Th17 cells are used to induce the disease (6). Th1 and
Th17 cells have a similar capacity to induce EAE, although
they differ in terms of the localization of CNS lesions and
the clinical disease symptoms (5). The transfer of autoreactive
Th17 cells mainly induced brain inflammation in recipient mice,
which developed atypical EAE, whereas the transfer of Th1
cells led to the development of classical EAE with predominant
spinal cord inflammation. Studies in MS patients and normal
human donors have provided evidence that Th1 and Th17
cells are active, particularly during the active disease phase, but
their contribution to the heterogeneous nature of the disease is
unclear (7–10).
Two-photon laser microscopy (TPLM) has helped to
characterize the dynamic behavior of autoreactive effector T
cells in the CNS during EAE. The subarachnoid space (SAS) and
cerebrospinal fluid (CSF) are preferential routes of entry for the
recruitment of T cells into the CNS during early phases of EAE.
Here, local antigen-presenting cells (APCs) display endogenous
antigens and activate the infiltrated T cells, guiding them into the
CNS parenchyma (11–14). Having reached the CNS, exogenous
myelin-specific CD4+ T cells injected into recipient EAE animals
are reactivated inside the spinal cord parenchyma by resident
and infiltrating APCs, sustaining the inflammatory process and
promoting demyelination and axonal damage (15–17). As seen
in the secondary lymphoid organs, where leukocyte motility
facilitates the efficient and rapid screening of professional
APCs (18), CD4+ T cell motility inside the SAS could favor
the reactivation of encephalitogenic T cells, a critical process
in the pathogenesis of MS and EAE. However, differences in
motility behavior between Th1 and Th17 cells inside the spinal
SAS during EAE have not been investigated, and the molecular
mechanisms controlling such processes remain unknown.
Integrins are heterodimeric transmembrane adhesion
molecules involved in leukocyte trafficking and are expressed
on the surface of a wide range of cell types in an inactive state.
Integrin–ligand binding is rapidly regulated by conformational
changes, as well as transcriptional induction and redistribution
from intracellular pools (19). The best-characterized β2-integrin
involved in leukocyte recruitment is LFA-1 (lymphocyte
function-associated antigen 1, also known as integrin αLβ2),
which participates in the rolling of circulating leukocytes on
the blood vessel wall, but predominantly mediates their firm
arrest on the vascular bed of lymphoid organs and at sites of
inflammation via interaction with its ligands, such as intercellular
adhesion molecule 1 (ICAM-1) (20). TPLM analysis has revealed
that LFA-1–ICAM-1 interactions also play a role in T cell firm
arrest during antigen recognition in lymph nodes and modulate
the amoeboid migration of T cells, facilitating antigen scanning
(21). However, the role of LFA-1 in the motility of T cells during
inflammation in the spinal SAS of EAE mice is still unknown.
Here we took an established method for the stable imaging of
the mouse spinal SAS (22) and adapted it for the lumbar region,
the main site of inflammation in C57BL/6 mice during EAE,
allowing stable imaging in living mice. We identified different
motility behaviors in Th1 and Th17 cells in the spinal SAS
of EAE mice and investigated the ability of LFA-1 to control
cell dynamics at the disease peak. Local anti-LFA-1 treatment
inhibited disease progression in EAE mice, supporting the view
that interfering with the local intra-tissue dynamics of effector
T cells may offer a valuable approach for the treatment of
autoimmune and inflammatory diseases of the CNS.
MATERIALS AND METHODS
Ethics Statement
All animal experiments were approved by the Italian Ministry
of Health, Department of Veterinary Public Health, Nutrition
and Food Safety, Directorate General of Animal Health and
Veterinary Medicine, as required by Italian legislation (D.
Lgs 26/2014, application of European Directive 2010/63/EU).
Protocol numbers 33588 and 30969 were assigned for the
approved animal experiments.
Mice
C57BL/6J wild-type (WT) mice and C57BL/6-Tg(Tcra2D2,
Tcrb2D2)1Kuch/J (2D2 TCR) transgenic mice carrying a T cell
receptor specific for the MOG35−55 peptide (23) were obtained
from The Jackson Laboratory. Animals were housed under
standardized conditions with a 12-h photoperiod in climate-
controlled facilities, and were provided with food and water ad
libitum. All animal experiments were supervised by the local
Institutional Animal Care Committee (OPBA) of the University
of Verona and were conducted according to current European
Community rules.
Production of MOG35−55-Specific Th1 and
Th17 Cells
Spleens were collected from 2D2 TCR transgenic mice, and a
single-cell suspension was prepared. Spleen cells were cultured
as previously described (24). Briefly, 20 × 106 cells per well
were cultured in a six-well plate for 7 days in the presence
of 20µg/ml MOG35−55 peptide (GenScript Corporation). For
Th1 polarization, we added 1 ng/ml IL-12 (R&D Systems) and
10µg/ml anti-IL-4 antibody (clone 11B11, hybridoma provided
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by E. C. Butcher, Stanford University). For Th17 cell polarization,
we added 5 ng/ml TGFβ, 20 ng/ml IL-6 and 20 ng/ml IL-23 (all
from Miltenyi Biotech or R&D Systems), as well as 10µg/ml
anti-IL-4 antibody (as above) and 10µg/ml anti-IFNγ antibody
(clone HB170, R&D Systems). Th1 cells were supplemented with
IL-2 (20 U/ml) and Th17 cells with IL-7 (10 ng/ml) after 4 days
in culture. After a further 72 h, MOG35−55-specific Th1 and
Th17 cells were isolated using a Ficoll-Paque density gradient
(GE Healthcare Life Sciences) and frozen in fetal calf serum
(FCS, Lonza) containing 10% dimethylsulfoxide (DMSO, Sigma-
Aldrich). Before use, the cells were thawed and re-stimulated
for 3 days in the presence of irradiated splenocytes as APCs
(APC:T cell ratio = 5:1) with the same peptide/cytokine cocktail
as described above. Th1 and Th17 cells were then isolated using a
Ficoll-Paque gradient and supplemented for one further day with
IL-2 or IL-7, as appropriate.
TPLM Preparation
Th1 or Th17 cells were labeled for 45min at 37◦C with
40mM CMAC or carboxyfluorescein-diacetate-succinimidyl-
ester (CFSE) (both from Molecular Probes). We then injected
2 × 107 Th1 or Th17 cells into the tail veins of MOG35−55-
immunized EAE recipient mice at different disease phases. In
order to ensure that the velocity data were not label dependent,
Th1 or Th17 cells labeled with CFSE and CMACwere co-injected
in equal proportions in preliminary experiments. No significant
difference was seen in the computation of dynamic parameters
or localization of Th1 and Th17 cells labeled with either CFSE or
CMAC. This agrees with previous studies showing that velocity
changes are not label dependent (25). Moreover, to exclude any
potential interference due to the different chemical structures of
the dyes, we reversed the dye combinations of Th1 and Th17 cells
in every experiment.
After 48 h, the mice were anesthetized by intraperitoneal
injection of ketamine (100 mg/kg body weight) and xylazine
(15 mg/kg body weight) solution and prepared for surgery. A
midline dorsal incision was made to expose the lumbar column
over L1-L4. Laminectomy was performed with a microdrill
and bone scraper to expose the spinal cord, leaving an intact
dura mater. Muscles were dissected from the sides of the
vertebral bone and a minor retraction of the paravertebral
muscles allowed the insertion of the fine-tipped clamps of a
spinal column stabilization device (Narishige STS-A Compact
Spinal Cord Clamps) fitted on a customized microscope stage
(Narishige MA-6N head holding adaptor on a steel base). This
adaptation of an earlier method (22, 26) achieves excellent
stability by combining the customized stabilization device
with deep anesthesia, minimizing respiratory movements. A
few drops of artificial CSF (Cold Spring Harb Protoc; 2011;
doi: 10.1101/pdb.rec065730) were added without a coverglass
to allow the direct immersion of the microscope objective.
Blood vessels were stained by the intravenous injection of Qdot
655 fluorescent quantum dots (Molecular Probes) immediately
before imaging.
TPLM Imaging
Mice, positioned on the stabilizing device andmaintained at 37◦C
using a thermostatic blanket system, were placed on a customized
upright Leica TCS SP5 AOBS confocal multiphoton system. The
three dyes (CMAC, CFSE and Qdot 655) were excited using a
mode-locked Ti:Sapphire Chameleon Ultra II laser (Coherent)
and visualized with an Olympus XLUMPlanFI 20× objective
(water immersed, numerical aperture, 0.95). For imaging, we
used simultaneous laser excitation at 750–800 nm. Fluorescence
emission from the three dyes was separated using panchromatic
electronic barrier filters and detected as red (560–650 nm), green
(490–560 nm) and blue (400–500 nm) signals. Stacks of images
were acquired using the Leica acquisition software. Our TPLM
system setup allowed us to visualize infiltrating T cells in the
whole dorsal spinal SAS thickness (Figure 1D) (12).
To create time-lapse sequences, we scanned volumes of tissue
in which each plane consisted of an image of 100 × 120µm (x
and y = 2 pixels/µm), whereas z-stacks were acquired by taking
28 sequential steps, 2.5µm apart for a total depth of 70µm, at
intervals of 35–40 s for up to 30min. To increase signal contrast,
we averaged two video frames for each z-slice. Multidimensional
rendering was accomplished using Imaris software (Bitplane).
In some experiments, immediately after the first acquisition of
Th1 and Th17 cell behavior, 200 µl of artificial CSF containing
100µg/ml of blocking anti-LFA-1 (clone M17/4, rat anti-mouse)
or control anti-Ras (clone Y13-259, rat anti-human/mouse/ rat)
monoclonal antibodies was locally applied to the exposed spinal
cord and incubated for 30–60min before a second round of
imaging, to allow adequate local meningeal diffusion and dural
lymphatic and CNS blood vessel recirculation (27).
TPLM Data Analysis
TPLM data were analyzed as previously described (28). Briefly,
sequences of image stacks were transformed into volume-
rendered three-dimensional movies, and cell movement was
analyzed using Imaris software. The three-dimensional spatial
position of each cell was detected based on centroid fluorescence
intensity. Cells were tracked over time manually and tracks
greater than 3min (≥12 time points) were included in the
analysis. Intra-tissue tracking of sufficient numbers of cells was
achieved by adhering to the following principles: (i) only fields
with at least 20 fluorescent leukocytes were considered for
analysis; (ii) a mean of four fields per mouse was examined; and
(iii) at least 100 manually tracked cells were considered under
each experimental condition. The following parameters were
calculated: instantaneous and mean cell velocity, arrest index,
meandering index, and cell displacement. Instantaneous velocity
provides a basic parameter derived from the displacement of the
cell centroid between adjacent time points. Track velocity was
obtained from the mean instantaneous velocity computed from
all time intervals throughout a track. The displacement of a cell
moving with a constant velocity from an initial position, but
randomly changing direction, is on average linearly proportional
to the square root of the elapsed time. The arrest index represents
the proportion of time during tracking in which a cell does not
move (threshold ≤ 2 µm/min) and it was calculated from cell
tracks, so the reported value represents a percentage of cells in
the entire population. The meandering index was also calculated
to provide another index of the directness of cell movement,
based on the ratio of displacement from origin by the total path
length (26).
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FIGURE 1 | Distribution of autoreactive T helper cells in the spinal SAS of EAE mice at the disease peak. (A) Representative image of autoreactive Th1 cell distribution
(blue) along the same focal plane of SAS pial vessels (red). Three-dimensional reconstitutions of the same image are shown without (B) and with (C) cell tracking
projections (yellow lines) based on a monitoring duration of 30min. (D) Schematic representation of a mouse spinal cord, highlighting the region scanned during our
TPLM imaging experiments (black box). The asterisk indicates the region where the blood vessel creeps into the white matter, becoming non-detectable to our
imaging system.
Cytoskeletal rearrangement during cell locomotion was
evaluated in terms of cell volume and cellular membrane
protrusions (29, 30) using Imaris software. In particular, cellular
protrusion analysis was carried out using the vertices generated in
Surface Mode. This function evaluates the curvature of a surface
by placing spots at each vertex and calculating curvature of these
spots with respect to their neighbors (30).
Isolation of Exogenous Infiltrating Th1 and
Th17 Cells From Spinal Cord
Forty-eight hours after the transfer of CMAC-labeled Th1 or
Th17 cells, C57BL/6 mice with actively-induced EAE were
perfused with phosphate-buffered saline (PBS) supplemented
with 1mM Ca2+/Mg2+. The spinal cords were then carefully
explanted, accurately homogenized with cold PBS using a
GentleMACS Octo Dissociator (Miltenyi Biotec), washed, and
incubated with 1 mg/ml collagenase (Sigma Aldrich) and 40
U/ml DNase (Thermo Fisher Scientific) for 45min at 37◦C.
Cell suspensions were prepared on a 70% Percoll gradient
(GE Healthcare).
Flow Cytometry
For the assessment of cytokine production, in vitro
differentiated Th1 and Th17 cells were stimulated for 12 h
with 50 ng/ml phorbol 12-myristate 13-acetate (PMA),
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1µg/ml ionomycin, and 10µg/ml brefeldin A. The cells
were then fixed and permeabilized using the Biolegend Fixation
buffer/Permeabilization wash buffer kit and labeled with
phycoerythrin (PE)-conjugated rat anti-mouse IFNγ (clone
REA638, Miltenyi Biotech) and eFluor660-conjugated rat
anti-mouse IL-17A (clone eBio17B7, eBioscience). Control
cells were stimulated under the same conditions, but without
brefeldin A. For the analysis of adhesion molecule expression,
in vitro differentiated and ex vivo labeled with 7-amino-4-
chloromethylcoumarin (CMAC; Molecular Probes) Th1 and
Th17 cells were stained with the following rat anti-mouse
monoclonal antibodies: APCFire750-conjugated anti-CD49d,
FITC-conjugated anti-CD11a/CD18, all from Biolegend.
For ex vivo studies, cell viability was confirmed using 7-
aminoactinomycin D (7AAD; eBioscience) and the mean
fluorescence intensity (MFI) of adhesion molecule expression
was calculated relative to CMAC+ infiltrating cells. We used a
MACSQuant Analyzer (Miltenyi Biotec) for the acquisition of
flow cytometry data, followed by analysis using FlowJo software.
EAE Induction and Antibody Treatment
C57BL/6J females (8–10 weeks old) were immunized
subcutaneously in the flanks with 100 µg of MOG35−55
peptide in 200 µl emulsion consisting of equal volumes of PBS
and complete Freund’s adjuvant (CFA; Difco Laboratories),
supplemented with 0.8 mg/mouse Mycobacterium tuberculosis
strain H37Ra (Difco Laboratories). Mice received 25 ng of
pertussis toxin (Alexis Biochemicals) intravenously at the time
of immunization and 48 h later. Clinical scores were recorded
daily as previously described (28). For therapeutic anti-LFA-1
treatment, mice were injected intracisternally with 10 µl PBS
containing 50 µg anti-LFA-1 antibody or the control anti-
Ras monoclonal antibody. Mice were injected the day after
disease onset and 4 days later. For intracisternal injection, each
mouse was anesthetized with a ketamine-xylazine solution as
above, the atlanto-occipital membrane was punctured with a
Hamilton syringe fitted with a 27-gauge needle, and the whole
antibody solution was administered in 2–3min (31, 32). To
exclude the possibility that antibody efflux from the CSF to
periphery might interfere with T cell recruitment in the CNS,
we also administered the anti-LFA-1 and control antibodies
intravenously as a negative control.
Immunohistochemistry Analysis
EAE mice were euthanized 3 days after the first intrathecal
antibody injection and 21 days post-immunization (dpi) for
neuropathology at late stages. Spinal cords were collected, frozen
and used to prepare 20-µm sections for histological staining with
hematoxylin/eosin and luxol fast blue to identify inflammatory
infiltrates and demyelination, respectively (33). Microglia were
stained using an anti-mouse ionized calcium binding adaptor
molecule-1 (Iba-1) antibody (Wako) as previously described
(34). All images were captured using a Leica DM6000B
microscope and Leica Application Suite software. We traced
the total cord area, posterior column area, gray matter area
and lateral, anterolateral, and anterior column areas (mm2),
which weremanually outlined and calculated using an automated
quantification system in ImageJ v1.49 (NIH) (35). Results from
the quantification of neuropathological findings on 4–6 cross-
sections of spinal cord per mouse taken at different lumbar and
thoracic levels were expressed as a percentage of white matter
area or total area.
Immunofluorescence Analysis
For the quantification of infiltrating CD3+ cells, frozen 20-µm
sections of spinal cord were stained with an Alexa488-conjugated
anti-CD3 antibody (clone 17A2, Biolegend) diluted 1:700, with
DAPI as a nuclear co-stain. All images were captured using Axio
Imager Z2 (Zeiss, Germany). Acquired images were quantified
using an in-house Python (https://www.python.org/) algorithm
that uses the OpenCV image analysis library. Results were then
represented as the area (µm2) of fluorescent CD3+ cells relative
to the total spinal cord area.
Statistics
Data are presented as means ± standard deviation (SD) or
standard error of the mean (SEM). A two-tailed Student’s t-
test was used to compare two groups. A P-value < 0.05 was
considered statistically significant. In TPLM studies, data are
expressed as means± SEM. Statistical significance was calculated
using the Mann–Whitney test, with a confidence interval of 95%.
In the plots of displacement and chemotactic index, we applied
linear regression and compared the slopes. Outliers identification
was calculated by Grubb’s test with a P-value < 0.05 considered
statistically significant.
RESULTS
Th1 and Th17 Cells Differentially Infiltrate
the Spinal SAS During the Phases of EAE
To study the intra-tissue behavior of effector T cells in
the spinal SAS of EAE mice, we generated Th1 and Th17
cells from 2D2 TCR transgenic mice (24) and confirmed
the polarization and phenotype of these cell subsets by
flow cytometry (Supplementary Figure 1). TPLM analysis was
carried out at different time points following immunization with
the MOG35−55 peptide. We observed the intra-tissue behavior of
labeled exogenous Th1 and Th17 cells at the following time points
after immunization: (i) pre-clinical phase, 9 dpi; (ii) disease
peak at 13–15 dpi; and (iii) chronic phase at 22–25 dpi. T cells
were injected 48 h before visualization. In order to compare
Th1 and Th17 cells within the same experiment, we used the
CFSE and CMAC dye combination. Because of the potential
effect of different dyes on motility, we reversed the cell type/dye
combinations between observations to balance the numbers of
experiments performed with each dye.
Th1 and Th17 cells showedmassive infiltration (∗∗P= 0.0096)
of the spinal SAS at the disease peak (mean clinical score = 4.0
± 0.5 SD) compared to the pre-clinical phase (mean clinical
score = 0 ± 0 SD) (Figure 2). However, we observed a
significant leakage of Qdots (the soluble vessel tracer) across
the vascular wall at the same time, suggesting impairment of
selective permeability in the blood–brain barrier. It was difficult
to visualize cells in areas with particularly severe leakage, and
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FIGURE 2 | Quantification of Th1 and Th17 cell accumulation in the spinal
SAS at different disease stages. MOG35−55-specific Th1 and Th17 cells were
injected into EAE mice during the pre-clinical phase (7 dpi), at the disease
peak (11–13 dpi) or during the chronic phase (20–23 dpi). TPLM imaging was
performed after 48 h. Cells were quantified by manual counting in the field
(volume) of acquisition. Data represent the mean ± SEM of six different fields
from three independent experiments. Th1 and Th17 cells quantification for
each disease stage was compared for statistical significance using the
Mann-Whitney test. For comparison between cell accumulation at different
disease stages Kruskal-Wallis test was applied (*P < 0.05; **P < 0.01).
such cells were therefore excluded from analysis. Although
the small number of cells observed during the preclinical and
chronic phases was insufficient for statistical evaluation, we
observed a tendency of Th1 and Th17 cells to reduce their speed
during disease progression. Taken together, these experimental
observations suggest a progressive increase in T cell activation
and antigen-dependent cell–cell contacts between T cells and
resident cells in the spinal SAS during the clinical phases of EAE,
with the chronic phase characterized by more antigen-dependent
phenomena even if the number of infiltrating Th1 and Th17 cells
was much lower (∗P = 0.023) than at the disease peak (mean
clinical score= 2.1± 0.7 SD) (Figure 2).
Particularly we found T cells spreading preferentially along
the same focal plane of SAS pial vessels, with very rare
cells located deeper, near to but not inside the dorsal spinal
cord white matter, probably crawling on leptomeningeal pial
membrane as previously described (12) (Figure 1). Moreover,
the myelinated nature of the CNS parenchyma limits TPLM
penetration, hampering the visualization of potential T cells
inside the spinal cord white matter (17, 36). Given this technical
limitation, TPLM studies on T cell motility in white and gray
matter parenchyma would require ex vivo acute spinal cord
explants (15).
Th1 and Th17 Cells Show Differential
Dynamics in the Spinal SAS of EAE Mice at
the Disease Peak
The preliminary experiments described above indicated that
exogenous pro-inflammatory Th1 and Th17 cells massively
infiltrate the spinal SAS at the disease peak, with significant
differences between cell types in terms of motility behavior.
To better understand these differences, we investigated Th1
and Th17 behavior in more detail in the inflamed spinal
SAS during the disease peak. Three-dimensional reconstitution
allowed us to discriminate between endothelium-extravasated
cells and those crawling on the luminal surface of the
vessels. We found very few cells crawling on the luminal
surface of the vessels, and we excluded these cells from
further analysis.
Notably, Th1 cells showed a significantly higher velocity than
Th17 cells (mean = 4.9 µm/min for Th1 cells but 3.7 µm/min
for Th17 cells, P < 0.0001) (Figure 3A). Also, the significantly
higher meandering index of Th1 cells (mean = 0.52 for Th1
cells and 0.40 for Th17 cells, P < 0.0001) suggested an increase
in directional bias (Figure 3B). Although the arrest index was
significantly higher in Th17 cells (0.1 for Th1 cells and 0.14
for Th17 cells, P < 0.0001) (Figure 3C). We defined three
subsets of extravasated cells: (i) stationary cells, comprising all
cells moving at a mean velocity ≤2 µm/min; (ii) perivascular
motile cells, comprising the cells moving close to the vascular
environment following the vessel wall, although among the
cells moving along the abluminal vascular surface we were
unable to distinguish cells moving between the endothelium and
basement membrane (perivascular cuff) from cells that were
completely extravasated; and (iii) non-perivascular motile cells,
specifically non-perivascular cells that were dispersed in the
SAS environment. Our analysis showed that ∼80% of the Th1
and Th17 cells displayed rapid movement, whereas 20% were
stationary. These latter cells were distributed preferentially close
to the vessel wall, anchored around a fixed point, suggesting
physical contacts with other resident cells, or moving slowly
in a looping pattern within a local area, behavior that was
previously termed “swarming” (18) (Figure 3D). Among the
motile Th1 cells, we distinguished a cell population showing
perivascular movement (20%), whereas the rest of the cells
were dispersed, moving inside the SAS (60%). The Th17 cells
showed similar behavior, with ∼30% of cells moving close to
the vessel walls and 50% moving in the SAS environment
(Figure 3D).
Analyzing the cells dispersed in the SAS in more detail,
we observed that Th1 cells moved in a straight line with a
characteristic rostro-caudal axis displacement, covering long
distances in both directions, whereas the Th17 cells exhibited
more restrained migration trajectories with a preference for
radial movement (Figures 4A,B and Supplementary Movies 1,
2). By plotting the displacement of these cells against the
square root of time, we found a linear plot for Th1
cells compatible with directed migration, whereas Th17 cells
displayed a plateau suggesting constrained motility (Figure 4C).
Furthermore, the instantaneous velocity data revealed that
Th1 cells meandered directly through the tissue with steady
movement, whereas Th17 cells showed stop-and-go behavior
as they migrated in the tissue (Figure 4D). Collectively, these
data suggest that the Th1 cells covered a greater area than the
Th17 cells.
Frontiers in Immunology | www.frontiersin.org 6 October 2019 | Volume 10 | Article 2436
Dusi et al. CNS Lymphocyte Motility During EAE
FIGURE 3 | Dynamics of Th1 and Th17 cell movement inside the spinal SAS at the EAE disease peak. Exogenous myelin-specific autoreactive Th1 and Th17 cells
were injected into EAE mice at the disease peak (11–13 dpi). TPLM imaging was performed on the exposed spinal cord 48 h later. The mean velocity (A), meandering
index (B) and arrest index (C) were calculated to compare the behavior of infiltrating cells. Data represent the mean ± SEM from a minimum of nine to a maximum of
490 cells from three independent experiments (***P < 0.0001). (D) Comparison of the dynamic behavior of the Th1 and Th17 populations. Data represent the mean ±
SEM of six different fields from three independent experiments.
Th1 and Th17 Cells Show Differential
Expression of LFA-1 in the Spinal SAS of
EAE Mice at the Disease Peak
The differential motility behavior of Th1 and Th17 cells
during the EAE disease peak indicated that different molecular
mechanisms are used by these cells to migrate in the spinal
SAS. To determine whether the contrasting dynamic behaviors
of these T cell subsets reflect distinct adhesive patterns, we
compared the expression of α4 integrins and LFA-1 in exogenous
in vitro differentiated Th1 and Th17 cells by flow cytometry
immediately before injection and inside isolated spinal cords
of EAE-induced mice 2 days after adoptive transfer at the
disease peak. We observed no differences in α4 integrin
expression between Th1 and Th17 cells (Figure 5A), but LFA-
1 was more abundant on Th1 cells both when comparing
cultured populations (MIF = 7423 in Th1 vs. 5560 in Th17cells,
∗P = 0.0159) and when comparing adoptively transferred cells
isolated from the spinal cords of recipient mice (MIF = 5866
in Th1 vs. 4127 in Th17cells, ∗P = 0.0286) (Figure 5B).
Interestingly, LFA-1 expression in the in vitro differentiated Th1
and Th17 cells was not affected in vivo by the spinal cord
microenvironment (Figure 5B). The differential expression of
LFA-1 in Th1 and Th17 cells potentially reflects their distinct
kinetics, related to the immune cell phenotype.
Blocking LFA-1 Affects the Motility
Behavior and Deformability of Moving Th1
Cells Dispersed in the Spinal SAS
We next investigated the potential role of integrin LFA-
1 in the regulation of Th1 cell motility in EAE mice at
the disease peak (mean clinical score = 4.3 ± 1.1 SD)
by the direct application of a blocking anti-LFA-1 antibody
(clone M17/4) to the exposed spinal cord. The inhibition
of LFA-1 activity reduced the mean velocity of Th1 cells
from 5.7 to 3.8 µm/min (P < 0.0001) (Figures 6A,B, and
Supplementary Movies 3, 4), whereas treatment with the control
antibody had no effect (Supplementary Figure 2). Interestingly,
we observed no significant change in the arrest index (from
0.25 to 0.30, P = 0.0959) after treatment, suggesting that Th1
cells were still moving but at a lower velocity (Figure 6C).
The meandering index was substantially lower after blocking
LFA-1 (falling from 0.62 to 0.37, P < 0.0001) (Figure 6D),
suggesting that LFA-1 controls the capacity of Th1 cells to
move in a straight line. Accordingly, we did not observe a
significant shift in the percentage of stationary cells (from 11.4
to 16.3%, P > 0.05) (Figure 7A). Furthermore, displacement
analysis focusing on the portion of moving Th1 cells dispersed
in the SAS (non-perivascular motile cells) showed a significant
reduction in the curve slope after blocking LFA-1 (P < 0.0001),
suggesting that Th1 cells were no longer able to move over
long distances covering much of the tissue volume (Figure 7B).
Overall, these data suggest that LFA-1 is needed for Th1 cells
to move in a straight line inside the spinal SAS at the EAE
disease peak.
Cell motility is a complex cellular process that involves
reorganization of the cytoskeleton. This reorganization includes a
dynamic rearrangement of the cortical actin cytoskeleton, which
is required for the development of cellular protrusions (including
lamellipodia and filopodia) and stress fibers. Cytoskeletal
rearrangement, in particular actin dynamics, is induced via
integrin by Rho-family GTPases (37). One possible explanation
for the dramatic impact of blocking LFA-1 activity on Th1
cell motility in the spinal SAS is the potential role of this
integrin in the cell deformation and cytoskeletal rearrangements
necessary for T cell migration. To test this hypothesis, we
compared the morphology of non-perivascular motile Th1 cells
before and after anti-LFA-1 antibody treatment. Generally, the
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FIGURE 4 | Non-perivascular motile Th1 and Th17 cell dynamics in the spinal SAS of EAE mice at the disease peak. (A) Representative images of autoreactive Th1
and Th17 cells moving in a dispersed manner in the SAS of EAE mice at the disease peak. Cell tracks (green lines) are also shown (scale bar = 50µm; red/orange
color = blood vessel). Time projections of 30min are shown. (B) Normalized trajectories of non-perivascular motile Th1 and Th17 cells. (C) Mean displacement of Th1
and Th17 cells. Data represent the mean ± SEM of at least 30 cells from three independent experiments. (D) Instantaneous velocities of three representative Th1 cells
(left panel) and Th17 cells (right panel). Cells moving at < 2 µm/min were considered non-motile.
initial response of a cell to a migration-promoting agent is to
polarize and extend protrusions in the direction of migration.
These protrusions can be large, broad lamellipodia or spike-like
filopodia, which can be quantified by counting the number
of vertices in each cell (30). Following LFA-1 inhibition, the
volume of Th1 cells was significantly lower compared to the
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FIGURE 5 | Integrin expression on Th1 and Th17 cells. The expression of α4
integrins (A) and LFA-1 (B) on Th1 and Th17 was evaluated both in vitro
before injection and ex vivo on exogenous CMAC+ T cells isolated from spinal
cords 48 h after adoptive transfer. Samples were analyzed by flow cytometry.
The mean fluorescence intensity (MIF) of LFA-1 was statistically higher on Th1
cells than Th17 cells both before injection and 48 h after cell transfer. Data
represent the mean ± SD of four mice per condition from two independent
experiments (*P < 0.05).
cells in untreated mice (704 vs. 1032 µm3, P < 0.0001)
and similarly the number of vertices decreased (639 vs. 823,
P < 0.0001) (Figures 7C,D,I), indicating that treated Th1 cells
moving in a dispersed manner in the spinal SAS become more
rounded and lower in volume, presumably because blocking
LFA-1 interferes with the cytoskeleton. Taken together, these
data suggest that blocking LFA-1 has a strong impact on
Th1 cell dynamics in the spinal SAS during EAE, probably
by disrupting cell deformability and the outside-in signaling
controlling cytoskeletal dynamics.
LFA-1 Controls the Motility Behavior of
Perivascular Th17 Cells
We next investigated the role of LFA-1 in the SAS dynamics
of Th17 cells during the EAE disease peak (mean clinical
score = 4.2 ± 1.4 SD). As observed for Th1 cells, blocking
LFA-1 affected the dynamics of Th17 cells, reducing their mean
velocity from 3.5 to 2.6 µm/min (P < 0.0001) (Figures 6E,F and
Supplementary Movies 5, 6). However, unlike Th1 cells, a large
proportion of Th17 cells became completely immotile following
the LFA-1 blockade. Indeed, we observed a strong increase in the
arrest index from 0.31 to 0.49 (P < 0.0001) (Figure 6G) with a
corresponding increment in the portion of non-motile cells from
12.5 to 47.5% (P < 0.05) (Figure 7E). The meandering index of
Th17 cells decreased after the inhibition of LFA-1 from 0.36 to
0.26 (P < 0.0001) (Figure 6H). Because the meandering index
of Th17 cells was lower than that of Th1 cells (Figure 3B), the
reduced meandering index of Th17 cells after blocking LFA-
1 was probably due to an increase in the proportion of non-
motile cells rather than changes in the motility behavior of
moving cells.
The analysis of moving Th17 cells dispersed in the spinal
SAS after antibody treatment suggested that blocking LFA-1 did
not affect the motility behavior of these cells, because the mean
displacement did not change (Figure 7F). Moreover, compared
to Th1 cells, the non-perivascular motile Th17 cells appeared
more rounded and less polarized due to their slower movement
(30) and, as expected, the volume and number of vertices of these
cells was unchanged after treatment (Figures 7G,H,J). These data
clearly show that LFA-1 controls the movement of perivascular
Th17 cells in the spinal SAS during EAE, but does not affect
either the velocity or deformability of non-perivascular motile
Th17 cells.
Intrathecal Injection of a Blocking
Anti-LFA-1 Antibody Inhibits the
Development of EAE
The motility of effector T cells in the SAS is regulated by resident
leptomeningeal cells and is necessary for their reactivation
and their pro-inflammatory role (11–14). For this reason, we
hypothesized that interfering with the local dynamics of T cells in
the spinal SAS may limit their pathogenicity and may ameliorate
EAE symptoms in immunized mice. To test this hypothesis, we
treatedMOG35−55-immunized EAEmice on the day after disease
onset and 4 days later by intrathecal injection with an anti-LFA-1
antibody or a control antibody. We found that the local blocking
of LFA-1 achieved the rapid and significant inhibition of disease
compared to the control group (Figure 8A, ∗P < 0.05). Disease
amelioration was associated with a significant decline in both
inflammatory cell infiltration (∗∗P = 0.0034) and demyelination
(∗∗∗P = 0.0003) in the anti-LFA-1 treated animals (Figure 8B).
Furthermore, the massive microgliosis in the lumbar spinal cord
of mice injected with the control antibody was attenuated in the
animals treated with anti-LFA-1, suggesting that the intrathecal
injection of the blocking antibody achieved a profound reduction
in the severity of CNS inflammation (Figure 8C, ∗∗∗P < 0.0001).
A second anti-LFA-1 injection further delayed the appearance
of the clinical peak in EAE mice (Figure 8A). Moreover, the
non-significant reduction in the quantity of infiltrating CD3+ T
cells in the lumbar spinal cords of mice treated with the anti-
LFA-1 antibody (P = 0.073) suggested that the inhibition of
LFA-1 blocks the function of T cells without eliminating them
(Figure 9). However, 5–6 days after the cessation of treatment,
the symptoms of EAE emerged and the mice reached a clinical
score comparable to control animals (Figure 8A). The mice
treated with the anti-LFA-1 antibody tended to display minor
neuropathological features at the late stage of EAE (21 dpi)
(Supplementary Figure 3). Moreover, except for inflammatory
infiltrating cells (P = 0.029) (Supplementary Figure 3A), we
observed no significant differences between the two groups of
treated animals. Notably, the comparison of early and late EAE
revealed that the neuropathology (in terms of infiltrates and
demyelination) following anti-LFA-1 antibody treatment was
preserved until disease chronicity, whereas in mice treated with
the control antibody, the amelioration of clinical symptoms was
associated with a tendency of reduction in inflammatory cell
infiltration (12.08 ±1.44 at 14 dpi vs. 8.18 ± 1.17 at 21 dpi,
P = 0.143) and demyelination (11.55 ± 1.45 at 14 dpi vs. 2.58
± 0.66, ∗∗∗P = 0.0002) (Supplementary Table 1).
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FIGURE 6 | An LFA-1 blockade differently affects autoreactive Th1 and Th17 cell dynamics in the spinal SAS at the EAE disease peak. Th1 and Th17 cell dynamics
were analyzed in the spinal SAS of EAE mice at the disease peak before (CTRL) and after the application of anti-LFA-1 antibodies to the exposed spinal cord. (A)
Representative images of Th1 cells moving in the spinal SAS before and after antibody treatment. (B) The mean velocity, (C) arrest index and (D) meandering index of
the Th1 cell population in the spinal SAS in the presence or absence of the anti-LFA-1 antibody (***P < 0.0001). (E) Representative images of Th17 cells moving in the
spinal SAS before (CTRL) and after antibody treatment. (F) The mean velocity, (G) arrest index and (H) meandering index of Th17 cells in the presence or absence of
the anti-LFA-1 antibody (***P < 0.0001). (A,E) Cell tracks (green lines) are also shown (scale bar = 50µm; red color = blood vessel). Time projections of 30min are
shown. In all graphs, data represent the mean ± SEM of 100 cells from three independent experiments.
Our intrathecal injection technique could potentially trigger
the rapid efflux of antibody from the CSF into the peripheral
lymphatic system and circulation, partly due to the increased
pressure in the CSF and to the massive leakage at the peak
of the disease. To rule the possibility that antibody efflux
interfered with leukocyte recruitment during the progression
of EAE, we also treated the MOG35−55-immunized EAE mice
with the anti-LFA-1 or control antibodies by intravenous
injection, with the same administration dose and timing used
for intrathecal treatment. We observed no significant differences
in EAE progression between the anti-LFA-1 and control mice
(Supplementary Figure 4). Collectively, these results suggest
that interfering with the local dynamics of effector T cells can
help to reduce their pathogenic potential and may therefore
offer a useful therapeutic strategy to control the progression of
autoimmune diseases.
DISCUSSION
Cells of the immune system communicate constantly with
the extracellular environment by releasing and sensing
soluble factors or through direct physical interactions with
surrounding cells. These processes are significant because they
influence cell proliferation, survival and effector functions.
In particular, the ability of T cells to scan APCs in secondary
lymphoid organs and to show dynamic behavior in the tissue
parenchyma of target organs is essential for the generation
and regulation of inflammatory responses (38). Recent studies
using TPLM have shown that the leptomeninges represent
a key checkpoint for T-cell infiltration into the CNS during
autoimmune inflammation (11–14, 17). Following extravasation,
T cells move on the abluminal vascular surface and pial
membrane, scanning the area for phagocytes that present
antigens. These contacts stimulate the effector T cells to
produce pro-inflammatory mediators, trigger tissue invasion
and guide infiltrating autoimmune T cells into the CNS
parenchyma (12, 17).
We used TPLM to visualize the spinal SAS and investigated
the dynamic motility of autoreactive Th1 and Th17 cells during
EAE, the murine model of MS. Our data revealed a previously
unappreciated difference in the behavior of these two effector
T cell populations suggesting that their pathogenic roles may
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FIGURE 7 | Blocking LFA-1 specifically affects non-perivascular motile Th1 cell dynamics and cell deformability in the SAS at the EAE disease peak. (A) Dynamic
properties of Th1 subpopulations are not affected by blocking LFA-1. (B) Mean displacement of non-perivascular motile Th1 cells is reduced by a LFA-1 blockade.
The volume (C) and number of vertices (D) of non-perivascular motile Th1 cells differ before (CTRL) and after the inhibition of LFA-1 (***P < 0.0001). (E) The dynamic
properties of the Th17 population: the number of perivascular motile Th17 cells is reduced following the application of an anti-LFA-1 antibody (*P < 0.05). (F) Mean
displacement of non-perivascular motile Th17 cells in the tissue is not affected after antibody treatment. The volume (G) and number of vertices (H) of
non-perivascular motile Th17 cells do not change after LFA-1 inhibition. (I) Representative images of non-perivascular motile Th1 cells before and after anti-LFA-1
treatment. Note the presence of highly-polarized cells before antibody application (left panel) and the predominant rounded cell morphology induced by blocking
LFA-1 (right panel) (scale bar = 15µm). (J) Blocking LFA-1 had no effect on non-perivascular motile Th17 cell cytoskeletal organization, compared to controls (scale
bar = 15µm). (B,F) Data represent the mean ± SEM of 100 cells from three independent experiments. (C,D,G,H) Data represent the mean ± SEM of 200 cells from
three independent experiments.
depend on their ability to move in the spinal SAS and to contact
resident cells.
Although there is evidence for the involvement of Th1 and
Th17 cells during the pathogenesis of MS and EAE (5, 9, 39–
41), the molecular mechanisms involved as these cells contribute
to the induction and progression of demyelinating diseases are
not well-understood. Importantly, the balance or predominance
of Th1 and Th17 responses in MS patients is correlated with
the heterogeneity of disease symptoms, variations in clinical
course, and the localization of CNS lesions (42–44). Importantly,
the physiological and pathological functions associated with
particular phenotypes of activated T cells, such as the production
of certain transcription factors and cytokines, are known to be
reversible (45).
It is now clear that studies in mouse models and humans,
showing the importance of Th1 or Th17 cells based solely on the
detection of their cytokines, are complicated by the plasticity of
activated T cell subsets. For example, committed cells producing
IL-17 readily convert to cells that produce IFNγ during the
course of EAE (46). In our experimental setting, the phenotype of
transplanted Th1 and Th17 cells differentiated in vitro remained
stable in the CNS. Importantly, we found that differences in LFA-
1 integrin expression between Th1 and Th17 cells before adoptive
transfer cells were maintained after 48 h of in vivo migration,
strongly suggesting that the phenotype of our cells does not
change in vivo during the first 2 days after cell transfer.
The movement of Th1 and Th17 cells inside the spinal cord
during the pre-clinical phase of actively-induced EAE is unclear.
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FIGURE 8 | Intrathecal injection of an anti-LFA-1 blocking antibody inhibits EAE progression in MOG35−55-immunized mice. (A) C57BL/6-immunized mice were
injected with 10 µl PBS containing 50 µg of control antibody (CTRL) (rat anti-human Ras, clone Y13259) or anti-LFA-1 blocking antibody. The mice were injected in
the cisterna magna the day after disease onset (11–13 dpi) and 4 days later (red arrows) and were then followed until 22 dpi and scored daily for the severity of clinical
disease symptoms. Data represent the mean ± SEM of 16 mice per condition from four independent experiments (*P < 0.05). (B) Neuropathology of EAE mice
treated with the anti-LFA-1 blocking antibody. Mice were euthanized 3 days after the first antibody injection (14 dpi), and spinal cords were analyzed for the presence
of inflammatory infiltrates and demyelination by hematoxylin/eosin and luxol fast blue staining, respectively. Representative consecutive spinal cord sections from mice
treated with control (CTRL) or anti-LFA-1 antibodies are shown (4–6 cross sections of spinal cord per mouse, n = 3 mice). Quantitative analysis of the infiltrated cells
and demyelination area for each condition. Error bars indicate SEM (**P < 0.005; ***P < 0.0005). Scale bar = 200µm. (C) Representative images of Iba-1+ microglia
in mice treated with a control or anti-LFA-1 antibodies. Quantitative analysis of microglial cells for each condition to determine the area occupied by Iba-1+ cells (4–6
cross sections of spinal cord per mouse, n = 3 mice per condition). Error bars indicate SEM (***P < 0.0005). Scale bar = 200µm (left) or 20µm (right).
Our results revealed only a few exogenous T cells infiltrating
the spinal SAS during the pre-clinical phase, in agreement with
previous reports showing limited injury to the blood–spinal cord
barrier during this phase (47, 48). Our results are also supported
by the data from a transfer EAE model in Lewis rats, which
revealed that most of the autoreactive transfected T cells were
distributed between the blood and peripheral lymphoid organs
during the prodromal phase (17, 49). We found that effector
T cells were not uniformly distributed in the tissue volume
we analyzed and observed small groups of both cell subsets in
specific areas of the spinal SAS, suggesting preferential entry
points. The rare activated cells that initially invade the CNS
are able to create a permissive environment, which is probably
not dependent on antigen presentation, setting the stage for
the second inflammatory wave, which contains antigen-specific
cells as well as other immune system cells with no antigen
specificity (50).
At the disease peak, we observed the massive infiltration
of Th1 and Th17 cells, with 20% of both populations in a
stationary state in close proximity to the vessel wall, suggesting
physical contacts with perivascular APCs (11–13). TPLSM
imaging allowed the visualization of dynamic contacts between
T cells and perivascular phagocytes, revealing that activation
signaling is not sufficient to completely arrest autoreactive T
cells in the SAS, and suggesting that contacts with APCs in
the leptomeningeal area are necessary to guide the infiltrating
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FIGURE 9 | Intrathecal injection of an anti-LFA-1 blocking antibody inhibits EAE progression T cells without eliminating CD3+ T cells in MOG35−55-immunized mice.
Mice were euthanized 3 days after the first antibody injection (14 dpi), and spinal cords were analyzed for the presence of CD3+ infiltrated cells by
immunofluorescence staining. Representative spinal cord sections from mice treated with control (CTRL) or anti-LFA-1 antibodies are shown (4–6 cross sections of
spinal cord per mouse, n = 3 mice). Quantitative analysis of the area occupied by CD3+ cells. Error bars indicate SEM. Scale bar = 200µm (left). Magnification of the
merged quadrant is shown in the right-hand images.
autoreactive T cells into the CNS parenchyma, rather than
causing their prolonged arrest (13). Among the portion of motile
Th1 and Th17 cells, it was possible to distinguish between the
majority of cells moving distantly from the vessels, dispersed in
the SAS structures of the spinal cord, and a smaller number of
cells that were following the vessel wall (perivascularmotile cells).
The dynamic nature of perivascular immune cells has previously
been reported in the CNS during EAE, indicating that CD4+ T
cell compartmentalization along CNS vessels is dependent on
the chemokine CXCR4, suggesting that the process is actively
promoted and may facilitate the efficient and rapid screening of
perivascular professional APCs (51). We found that Th17 cells
displayed more constrained stop-and-go motility, whereas Th1
cells moved directly along the axis of the spinal cord parallel
to the main central vein, suggesting a rostro-caudal biased walk
with confined lateral movement (52). This previously unreported
difference between Th1 and Th17 cell motility behavior suggests
that these populations play distinct roles during the induction of
EAE (42, 53).
Compared to mesenchymal and epithelial cells, leukocytes
(including T cells) exhibit a peculiar migration behavior
known as amoeboid migration. Three biomechanical factors
facilitate amoeboid cell motility: integrin-mediated adhesion,
leading edge protrusion driven by actin polymerization, and
myosin II-mediated contractility (54). Due to their amoeboid
movement, T cells can navigate through many tissues and
organs, including blood vessels, secondary lymphoid organs,
and peripheral tissues, to perform their immune surveillance
and immune response functions (55). CD4+ T cell motility
is actively promoted in the CNS during EAE. Pre-existing
scaffolds guide lymphocyte migration in lymphoid tissues,
and specialized structures are induced in the leptomeningeal
area during CNS inflammation to guide T cell migration,
potentially facilitating the screening of APCs and integrating
relevant stimulatory costimulatory, and regulatory signals. The
arachnoid membrane, trabeculae and pia mater, which make
up the SAS, are always immersed in CSF and must be
exposed to its immunological influence. Chronic inflammation
may trigger the maturation of immunostimulatory trabecular
fibroblast-like cells in organized ectopic aggregates, commonly
described as tertiary lymphoid tissues (56). Moreover, during
CNS inflammation, these trabecular fibroblast-like cells could
regulate immune cell entry into the SAS from the bloodstream
and control the transition of inflammatory responses from
regions proximal to CNS barriers into the parenchyma (57).
Notably, chronic inflammatory conditions during MS and
EAE induce the organization of a lymphoid-like tissue in
which fibroblastic networks secrete extracellular matrix (ECM)
components, chemokines and cytokines and upregulate ICAM-
1 expression (58–62). Recent studies suggest a role for
integrins as receptors for stromal cells and the ECM in
neurological disorders, because they represent an important link
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between the ECM, the intracellular cytoskeleton, and signaling
pathways (63).
Our data show that integrin LFA-1 is necessary, in different
ways, for Th1 and Th17 cell trafficking in the spinal SAS
during the EAE disease peak. Interestingly, anti-LFA-1 treatment
significantly reduced the rate of Th1 cell movement and affected
their directed movement in the SAS, while increasing the
number of perivascular non-motile Th17 cells. The strong
impact of LFA-1 inhibition on T cell dynamics in the SAS
is supported by earlier reports showing that both LFA-1
and its ligand ICAM-1 (expressed on dendritic cells) are
required for the rapid interstitial migration of lymphocytes
in the lymph node parenchyma (21). Similar results were
recorded following the pretreatment of T cells with inhibitors
of actin organization, indicating that cytoskeletal rearrangement
is required for the rapid, directed motility of T cells in
lymph nodes (21). Our cellular morphology data revealed that
Th1 cells lost volume and the capacity to extend cellular
protrusions during their movement when LFA-1 was inhibited,
suggesting that LFA-1 is actively involved in the cytoskeletal
rearrangements necessary for amoeboid migration (64). On
the other hand, integrins were found to be unnecessary
for amoeboid movement maintained by the presence of
chemokines, which support the movement despite the absence
of adhesive interactions (65). However, in our study, non-
perivascular motile Th1 cells moved in a straight line, but in
both directions, which does not indicate the presence of a
chemotactic factor.
The LFA-1 blockade did not change the motility or
morphology of the moving Th17 cells dispersed in the SAS
environment, even though these cells were moving at a slower
velocity than the Th1 cells. In such a scenario, we propose that
the selective inhibitory effect on the motility of Th1 cells may
reflect the greater abundance of LFA-1 on Th1 compared to Th17
cells. Moreover, the LFA-1 blockade dramatically inhibited the
movement of Th17 cells in close proximity to the perivascular
environment, so the role of LFA-1 in the motility of these
cells remains unclear and further experiments are required to
understand which adhesionmolecules are involved.We speculate
that blocking LFA-1 could interfere with the sub-endothelial
crawling of Th17 cells along pericytes as demonstrated for
neutrophils. Indeed, the abluminal crawling of neutrophils is
supported by ICAM-1 (expressed by pericytes) and its leukocyte
integrin ligands, Mac-1 and LFA-1 (66). Moreover, stimulated
trabecular fibroblast-like cells were shown to enhance the
expression of ICAM-1, perhaps facilitating their interaction
with incoming extravasated Th17 cells (59, 67). ICAM-1 is
expressed on the trabecular network, the cellular surface lining
the CSF system, and seems to promote leukocyte migration
independently of the vascular system (67).
A recent study described the inhibition of intraluminal
crawling T cells following the intravenous co-application of anti-
LFA-1 and anti-VLA-4 antibodies 2 days after adoptive transfer,
when the majority of T cells are still closely related to the
vessels wall, with only 2% of the cells detached from vessels (12).
However, in our study, we demonstrate for the first time that
LFA-1 plays a key role in the motility of Th1 cells inside SAS
after extravasation from the pial vessels, probably as these cells
are attempting to reach the CNS parenchyma.
Our experiments revealed that the intrathecal injection of an
anti-LFA-1 antibody after the onset of EAE has a significant
impact on disease progression, suggesting that interfering with
the motility of activated T cells in the CNS could offer a new
approach for the treatment of autoimmune diseases such as
MS. However, LFA-1 is also required for the generation of a
functional immunological synapse during antigen presentation
to T lymphocytes by APCs in secondary lymphoid organs (68).
This process may also be important during T cell reactivation
by local APCs in the CNS (15), and the confined inhibition
of LFA-1 in the CNS of EAE mice may also limit effector T
cell reactivation in the CNS parenchyma. Furthermore, TPLM
analysis has shown that Th17 cells form synapse-like contacts
with neurons in a process dependent on LFA-1/ICAM-1, leading
to neuronal dysfunction and axonal damage during EAE (69).
LFA-1 is also implicated in the sequestration and accumulation
of activated T cells in the leptomeningeal milieu, a key process
required for the infiltration of T cells into the CNS parenchyma
during EAE (70). Therefore, we cannot exclude the possibility
that local anti-LFA-1 treatment might affect not only T cell
motility in the spinal SAS, but also T cell reactivation and
contacts with leptomeningeal and neural cells, as well as other
immunological and non-immunological processes inside the
CNS. Moreover, the disease returns with equal severity once the
treatment period is over, suggesting that the local LFA-1 blockade
exerts a protective mechanism (71, 72). Further studies are
therefore required to clarify the effects of anti-LFA-1 treatment
on CNS local inflammatory responses during EAE.
Integrins are valuable therapeutic targets for the treatment of
several inflammatory and autoimmune diseases, but the severe
side effects associated with systemic treatment have led to the
discontinuation of several clinical trials (73, 74). In MS, the
anti-α4 integrin antibody natalizumab is currently indicated
for the treatment of relapsing-remitting forms of the disease,
even though in some patients it causes the reactivation of
John Cunningham (JC) virus in the CNS, probably due to
interference with immune surveillance mechanisms (75). The
intrathecal administration of certain therapeutic proteins is
therefore emerging as an alternative to systemic therapy. For
example, intrathecal administration has been used to deliver
enzymes as a treatment for brain storage diseases in rodents and
humans, Nogo-A protein in stroke models, and trastuzumab in
patients with breast cancer brain metastases (76). The intrathecal
injection of antibodies interfering with effector T cell dynamics
in the CNS may complement existing MS therapies and, if
administered at the onset of relapse, may lead to a faster
resolution and therefore inhibit chronic disease progression,
without impairing systemic immunity.
Taken together, our results suggest that LFA-1 is needed to
control effector T cell motility in the spinal cord under the
inflammatory conditions of the EAE disease peak. As well as
improving the understanding of immune cell involvement in
neurological diseases, our data suggest that local anti-LFA-1
antibodies could also be used for the treatment of neurological
and autoimmune diseases.
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Supplementary Figure 1 | Cytokine production by Th1 and Th17 cells. IFNγ and
IL-17A production by Th1 and Th17 cells was evaluated on the day of cell
injection in EAE recipient mice. Samples were analyzed by flow cytometry.
Approximately 40% of Th1 cells produced IFNγ and more than 40% of Th17 cells
produced IL-17A with negligible INFγ production.
Supplementary Figure 2 | Effect of a control antibody on Th1 and Th17 motility
in the spinal SAS of EAE mice at the disease peak. Th1 and Th17 cell motility
behavior was evaluated in the spinal cord at the disease peak before and after the
administration of a control antibody (rat anti- human Ras, clone Y13259). Antibody
administration did not affect the velocity (A,D), motility (B,E), and meandering
index (C,F) of either the Th1 or Th17 cells. Data in all graphs represent the mean
± SEM of 50–100 cells from two independent experiments.
Supplementary Figure 3 | Neuropathology of late stage EAE in
MOG35−55-immunized mice following the intrathecal injection of an anti-LFA-1
blocking antibody. (A) Immunized C57BL/6 mice were injected with 10 µl PBS
containing 50 µg of a control antibody (CTRL) (rat anti-human Ras, clone Y13259)
or an anti-LFA-1 blocking antibody. The mice were injected in the cisterna magna
the day after disease onset (11-13 dpi) and 4 days later. (A) Quantification of
neuropathology of EAE mice treated with the anti-LFA-1 blocking antibody. Mice
were euthanized 21 dpi and spinal cords were analyzed for the presence of
inflammatory infiltrates (A), CD3+ T cells (B), demyelination (C), and Iba-1+
microglia (D). Error bars indicate SEM (∗P < 0.05).
Supplementary Figure 4 | Intravenous injection of an anti-LFA-1 blocking
antibody does not significantly affect EAE progression in MOG35−55-immunized
mice. Immunized C57BL/6 mice were injected intravenously with 200 µl PBS
containing 50 µg of a control antibody (CTRL) (rat anti- human Ras, clone Y13259)
or an anti-LFA-1 blocking antibody. The mice were injected the day after disease
onset (11-13 dpi) and 4 days later (red arrows) and were then followed until 22 dpi
and scored daily for the severity of clinical disease symptoms. Data represent the
mean ± SEM of eight mice per condition. The intravenous anti-LFA-1 antibody
administered at the same dose used for the intrathecal treatment did not
significantly affect EAE progression during the observation period.
Supplementary Movie 1 | Non-perivascular motile Th1 cell dynamics in the SAS.
Representative tracks of MOG35−55-specific Th1 cells (blue cells) moving in the
meningeal spinal cord structures of MOG35−55-immunized mice at the EAE
disease peak (clinical score = 4). This video shows how Th1 cells move in straight
lines covering long distances in the spinal cord meningeal structures. Vascular
permeability is visualized by the leakage of red dye into the extravascular space,
as indicated by the yellow ring. Vessels are shown in red. Scale bar = 50 µm.
Supplementary Movie 2 | Non-perivascular motile Th17 cell dynamics in the
SAS. Representative tracks of MOG35−55-specific Th17 cells (green cells) moving
in the meningeal spinal cord structures of MOG35−55-immunized mice at the EAE
disease peak (clinical score = 4). This video shows how Th17 cells display more
constrained migration. Vessels are shown in red. Vascular permeability is
visualized by the leakage of red dye into the extravascular space, as indicated by
the yellow ring. Scale bar = 50 µm.
Supplementary Movies 3 and 4 | Th1 cells moving in the SAS before and after
anti-LFA-1 treatment. These videos show representative tracks of total
MOG35−55-specific Th1 cells (blue cells) moving inside spinal cord leptomeninges
of MOG35−55-immunized mice at the EAE disease peak (clinical score = 4) before
(movie 3) and after (movie 4) the local administration of an anti-LFA-1 antibody.
Blocking LFA-1 led to a reduction in Th1 cell velocity, interfering with their
straight-line motility. Notably, non-perivascular motile Th1 cells were mainly
affected, whereas the motility of perivascular Th1 cells was unaffected. Vessels are
shown in red. Scale bar = 50 µm.
Supplementary Movies 5 and 6 | Th17 cells moving in the SAS before and after
anti-LFA-1 treatment. These videos show representative tracks of total
MOG35−55-specific Th17 cells (blue cells) moving inside the spinal cord
leptomeninges of MOG35−55-immunized mice at the EAE disease peak (clinical
score = 4) before (movie 5) and after (movie 6) the local administration of an
anti-LFA-1 antibody. Blocking LFA-1 mainly affected the dynamics of perivascular
motile Th17 cells, resulting in a substantial loss of movement. Vessels are shown
in red. In movie 6, vascular permeability is visualized by the leakage of red dye into
the extravascular space, as indicated by the yellow ring. Scale bar = 50 µm.
Supplementary Table 1 | Neuropathology of EAE mice treated intrathecally with
the anti-LFA-1 blocking antibody. Mice were euthanized 3 days after the first
antibody injection (14 dpi) and during chronic phase (21 dpi). Spinal cords were
analyzed for the presence of inflammatory infiltrates, demyelination, and Iba-1+
microglia. Results are expressed in mean ± SEM of 4-6 cross sections of spinal
cord per mouse. (n = 3 mice per condition). Statistics were calculated using the
Mann–Whitney test, with a confidence interval of 95%.
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